Lazertinib( YH 25448 | YH25448 | GNS-1480 | GNS1480 )

Catalog No. M12983 CAS No. 1903008-80-9

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Group Booking Get Quotation Bulk Inquiry Add to Cart

Product Name

Lazertinib
Note

Research use only, not for human use.
Brief Description

Lazertinib (YH25448, GNS-1480) is a highly potent, mutant-selective, irreversible, brain-penetrant and orally active EGFR tyrosine-kinase inhibitors for both the T790M mutation and activating EGFR mutations.
Description

Lazertinib (YH25448, GNS-1480) is a highly potent, mutant-selective, irreversible, brain-penetrant and orally active EGFR tyrosine-kinase inhibitors for both the T790M mutation and activating EGFR mutations; shows the beneficial for the NSCLC with brain metastasis.Lung Cancer Phase 2 Clinical.
In Vitro

——
In Vivo

——
Synonyms

YH 25448 | YH25448 | GNS-1480 | GNS1480
Pathway

Angiogenesis
Target

EGFR
Recptor

EGFR (del19)|EGFR (T790M)|EGFR (T790M/L858R)
Research Area

Cancer
Indication

Lung Cancer

CAS Number

1903008-80-9
Formula Weight

554.66
Molecular Formula

C30H34N8O3
Purity

>98% (HPLC)
Solubility

Ethanol: Insoluble; Water: Insoluble; DMSO: 10 mg/mL （ < 1 mg/ml refers to the product slightly soluble or insoluble )
SMILES

C=CC(NC1=CC(NC2=NC=CC(N3N=C(C4=CC=CC=C4)C(CN(C)C)=C3)=N2)=C(OC)C=C1N5CCOCC5)=O
Chemical Name

N-{5-[(4-{4-[(dimethylamino)methyl]-3-phenyl-1H-pyrazol-1-yl}pyrimidin-2-yl)amino]-4-methoxy-2-(morpholin-4-yl)phenyl}prop-2-enamide

1. Patent US20160102076 A1. 2.?Yun J, et al. Clin Cancer Res. 2019 Jan 22. pii: clincanres.2906.2018. doi: 10.1158/1078-0432.CCR-18-2906.

Calculator

molnova catalog